X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BPX-601 incorporates high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA). It is being discontinued following the company’s assessment of BPX-601 risk/benefit profile in combination with rimiducid.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-601
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
BPX-601 is our first clinical candidate incorporating our high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA).
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-601
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Proceeds from the financing will be used to support ongoing clinical development of BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-601
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: MTS Securities
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 06, 2021
Details:
Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs. The CaspaCIDe switch consists of the CID-binding domain coupled to the signaling domain of caspase-9, an enzyme that is part of the apoptotic pathway.
Lead Product(s): Cellular Therapy,Inducible Caspase-9,Rimiducid
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Licensing Agreement September 01, 2021
Details:
BPX-603 is Bellicum’s first dual switch GoCAR-T product candidate that incorporates the company’s iMC activation and CaspaCIDe safety switch technologies. Phase 1/2 trial will investigate the safety, tolerability, and clinical activity of BPX-603, administered with rimiducid.
Lead Product(s): BPX-603,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-603
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
The FDA is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. The clinical investigator and Bellicum classified the patient death as unrelated to BPX-601 and rimiducid.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-601
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Findings from the first four patients treated with BPX-601 followed by repeat rimiducid dosing showed evidence of rimiducid-mediated CAR-T cell activation. Clinically meaningful efficacy as measured by RECIST criteria was not observed.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: BPX-601
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
BPX-603 is the company’s first dual-switch GoCAR-T® product candidate, which incorporates both the company’s iMC activation and CaspaCIDe® safety switch technologies.
Lead Product(s): BPX-603
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
Bellicum is currently involved in 12 active studies, including a phase 1/2 trial of BPX-601 CAR-T cells in advanced solid tumors that express high levels of PSCA.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2020
Details:
A cohort treated with BPX-601 and a single dose of rimiducid showed immunomodulation in both the periphery and tumor microenvironment.
Lead Product(s): BPX-601,Rimiducid
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
